Cytovation ASA

Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic material from within the cancer cells, and induces a tumor-specific immune response. The described mode of action is effective across cancer types and highly synergistic with checkpoint inhibitors. CyPep-1 has entered clinical development in Q1 2019.